Human Prostate Cancer Peripheral Blood Mononuclear Cells

Description

Human Prostate Cancer Peripheral Blood Mononuclear Cells (PBMCs) are immune cells isolated from the peripheral blood of prostate cancer patients. These PBMCs contain T cells, B cells, NK cells, and monocytes that exhibit characteristic prostate cancer-associated immune alterations. These cells reflect the progressive immunosuppression characteristic of prostate cancer, showing elevated Treg population (CD4⁺CD25⁺FoxP3⁺), increased myeloid-derived suppressor cells (CD33⁺HLA-DR⁻), and exhausted CD8⁺ T cells expressing PD-1, TIM-3, and LAG-3—hallmarks of the tumor’s ability to evade immune surveillance. Additionally, these cells exhibit disease-specific features including androgen receptor signaling-influenced immune profiles and PSMA (prostate-specific membrane antigen)-reactive T cell populations. These features make them particularly valuable for studying the dynamic interplay between hormonal therapy and immune function in prostate cancer progression. These prostate cancer PBMC provide a vital resource for investigating immune cells in prostate cancer and enable detailed characterization of peripheral blood mononuclear cells prostate cancer for studies on disease progression and immunotherapy response.